A malaria vaccine that is 77 per cent effective in clinical trials has been approved for use in children 3 to 5 years old, the group most vulnerable to dying from the disease
A malaria vaccine that is 77 per cent effective in clinical trials has been approved for use in children 3 to 5 years old, the group most vulnerable to dying from the disease